(Q38868724)

7 September 2017

title

Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1. (English)

1 reference

7 September 2017

main subject

anti-retroviral agent

0 references

1 reference

P Kasirye

1

0 references

Diana M Gibb

12

object named as

D M Gibb

1 reference

7 September 2017

13

A S Walker

1 reference

7 September 2017

14

ARROW Trial Team

1 reference

7 September 2017

Patricia Nahirya-Ntege

7

object named as

P Nahirya-Ntege

1 reference

7 September 2017

L Kendall

2

1 reference

7 September 2017

K K Adkison

3

1 reference

7 September 2017

C Tumusiime

4

1 reference

7 September 2017

M Ssenyonga

5

1 reference

7 September 2017

S Bakeera-Kitaka

6

1 reference

7 September 2017

T Mhute

8

1 reference

7 September 2017

A Kekitiinwa

9

1 reference

7 September 2017

W Snowden

10

1 reference

7 September 2017

D M Burger

11

1 reference

7 September 2017

language of work or name

English

0 references

publication date

21 December 2011

1 reference

Clinical Pharmacology & Therapeutics

7 September 2017

published in

1 reference

7 September 2017

volume

91

1 reference

7 September 2017

issue

2

1 reference

7 September 2017

page(s)

272-280

1 reference

Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working Group

7 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.225

A model-based approach to dose selection in early pediatric development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.225

Clinical pharmacokinetics of lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.225

Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.225

Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.225

Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.225

Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-<36 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.225

A chewable pediatric fixed-dose combination tablet of stavudine, lamivudine, and nevirapine: pharmacokinetics and safety compared with the individual liquid formulations in human immunodeficiency virus-infected children in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.225

Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.225

Age-dependent pharmacokinetics of lamivudine in HIV-infected children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.225

Pharmacokinetics and safety of single oral doses of emtricitabine in human immunodeficiency virus-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.225

Nucleoside reverse transcriptase inhibitors in combination therapy for HIV patients: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.225

Ensuring the involvement of children in the evaluation of new tuberculosis treatment regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.225

Population pharmacokinetics of lamivudine in human immunodeficiency virus-exposed and -infected infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.225

Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice daily

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.225

A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.225

A phase I/II study of 2'-deoxy-3'-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.225

Comparison of the plasma pharmacokinetics of lamivudine during twice and once daily administration in patients with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.225

Abacavir/lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with each component administered concurrently and the effect of food on absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.225

Increasing antiretroviral drug access for children with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.225

inferred from DOI database lookup

7 January 2021

based on heuristic

Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.225

inferred from DOI database lookup

7 January 2021

based on heuristic

Population pharmacokinetics of lamivudine in adult human immunodeficiency virus-infected patients enrolled in two phase III clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.225

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/CLPT.2011.225

1 reference

7 September 2017

1 reference